Renoprotection of angiotensin receptor blockers: Beyond blood pressure lowering

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 846-849

  Miyata, Toshio ^a   van Ypersele de Strihou, Charles ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Advanced glycation end products; Blood pressure; Chronic hypoxia; Diabetic nephropathy; Oxidative stress; PAI 1; Renin angiotensin system

Indexed keywords

AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; OLMESARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDOXAMINE; TM 2002; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; RENAL PROTECTION; STRUCTURE ACTIVITY RELATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 33645281940     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl013     Document Type: Editorial

References (30)

1. Mogensen CE. Diabetes and hypertension. Lancet 1979; 1: 388-389
2. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179
3. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
4. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
5. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
6. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
7. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678
8. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
9. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: A pilot study. Am J Nephrol 2004; 24: 340-345
10. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: A double-blind randomized cross-over study. Diabetes Care 2003; 26: 150-155
11. Tominaga N, Robert A, Izuhara Y et al. Optimal doses of angiotensin receptor type 1 blockers for blood pressure lowering and renoprotection in a type 2 diabetic nephropathy rat model. (submitted)
12. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 2005; 67: 799-812
13. Seikaly MG, Arant BS, Seney FD. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86: 1352-1357
14. Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487
15. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-3282
16. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999; 55: 389-399
17. Izuhara Y, Nangaku M, Inagi R et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631-3641
18. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222
19. Nangaku M, Izuhara Y, Usuda N et al. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant 2005; 20: 2661-2669
20. Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997; 100: 2995-3004
21. Monnier VM. Transition metals redox: Reviving an old plot for diabetic vascular disease. J Clin Invest 2001; 107: 799-801
22. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897
23. Inagi R, Yamamoto Y, Nangaku M et al. A severe diabetic nephropathy model with early development of nodular-like lesions induced by megsin overexpression in the RAGE/iNOS transgenic mice. Diabetes 2006; 55: 1-11
24. Tanaka T, Miyata T, Inagi R, Fujita T, Nangaku M. Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol 2004; 165: 1979-1992
25. Shao J, Nangaku M, Miyata T et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31-38
26. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal diseases. Am J Kidney Dis 1992; 20: 580-584
27. Isizaka N, Aizawa T, Yamazaki L et al. Abnormal iron deposition renal cells in the rat with chronic angiotesin II administration. Lab Invest 2002; 82: 87-96
28. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-F220
29. Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343-348
30. Izuhara Y, Nangaku M, Shao J et al. A novel inhibitor of advanced glycation: Its benefits for renal damage in rat models. (submitted)